Introduction
============

Cancer treatment with agents such as cisplatin has a well-known association with nausea and emesis via mechanisms that are believed to predominantly involve the release of 5-hydroytryptamine (5-HT) in the gastrointestinal tract, which activates vagal afferents, but also a release of substance P in the brainstem to activate tachykinin NK~1~ receptors. Inflammatory mediators may also be involved, and 5-HT~3~ receptors may play a role in the dorsal vagal complex of the brainstem ([@B54]; [@B26]; [@B4]). Guidelines for nausea and emesis control involve a combination of 5-HT~3~ and tachykinin NK~1~ receptor antagonists plus a glucocorticoid such as dexamethasone ([@B52]). Second-generation 5-HT~3~ receptor antagonists (e.g., palonosetron) and NK~1~ receptor antagonists (e.g., netupitant) are now available and have greater potency and/or more favorable pharmacokinetics than older-generation compounds, which is reflected in their superior clinical efficacy ([@B27]; [@B45]; [@B57]). Yet despite these advances, a proportion of patients still have inadequate protection from chemotherapy-induced nausea and emesis ([@B24]; [@B71]).

Ghrelin is a peptide that stimulates feeding and gastrointestinal motility via growth hormone secretagogue receptors (GHS-R1A) ([@B46]; [@B61]; [@B43]). We previously demonstrated that ghrelin could antagonize cisplatin-induced acute emesis in ferrets via central actions in the brain ([@B58]). Since then, studies in man have shown that ghrelin can improve the control of chemotherapy-induced nausea and emesis and increase appetite when combined with the 5-HT~3~ receptor antagonist, ramosetron ([@B28]). Ghrelin mimetics may be useful in other situations to treat nausea and emesis. Anamorelin has shown particular benefit in patients with cancer cachexia ([@B16]); relamorelin has shown benefit in patients with diabetic gastroparesis via enhancement of gastric emptying and reduction of emesis ([@B12]); and ulimorelin has shown benefit in patients with postoperative ileus, in whom it reduced nausea and emesis ([@B63]).

Surprisingly, no studies have been conducted to determine whether ghrelin or ghrelin mimetics have broad inhibitory anti-emetic properties. In this study, therefore, we investigated the potential of the new and recently synthesized orally bioavailable brain-penetrating ghrelin mimetic -- HM01 (1-\[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl\]-3-methyl-3-\[(4R)-1-Methyl-3,3-dimethyl-4-piperidyl\]urea; **Figure [1](#F1){ref-type="fig"}**) -- to inhibit emesis induced by nicotine, which is presumed to induce emesis via central mechanisms that involve the area postrema and/or autonomic nervous system ([@B36]; [@B7]), and to inhibit emesis induced by intragastric copper sulfate, which is presumed to induce emesis via peripheral vagal and splanchnic pathways from the gastrointestinal tract ([@B73]; [@B33]). We also investigated the potential of HM01 to antagonize emesis induced by motion, which involves sensory conflict and mechanisms that traverse the brainstem via the vestibular nuclei ([@B48]; [@B8]).

![The chemical structure of HM01.](fphar-09-00869-g001){#F1}

It is feasible that ghrelin mimetics could be used in combination with standard anti-emetics for the treatment of chemotherapy-induced nausea and emesis, so we evaluated HM01 for the potential to antagonize cisplatin-induced emesis, both alone and in combination with palonosetron and/or netupitant ([@B27]). Ghrelin and HM01 are well known to increase appetite and food consumption ([@B34]; [@B43]; [@B72]). Therefore, most experiments in our study simultaneously assessed drug action on food and water consumption. We envisaged that an ability of a treatment to increase feeding during or after emetic treatments might provide an index to indicate the potential to reduce nausea. Common laboratory animals (e.g., mice, rats) are incapable of vomiting, so these studies used *Suncus murinus*, a species commonly used in research into mechanisms of acute chemotherapy- and motion-induced emesis ([@B60]; [@B50]). The amino acid sequence and cDNA sequence of ghrelin and its mRNA distribution in various tissues has been reported in this species ([@B30]; [@B65]). Moreover, the role of ghrelin in the mechanisms of gastrointestinal motility and gastric acid production has also been characterized in *Suncus murinus* ([@B41]; [@B42]). It was thought that these studies would provide more insight into the role of GHS-R1A in the mechanism of emesis control necessary for the development of ghrelin mimetics as novel anti-emetic drugs.

Materials and Methods {#s1}
=====================

Animals
-------

Male *Suncus murinus* (45--65 g) were obtained from the Chinese University of Hong Kong and housed in a temperature-controlled room at 24°C ± 1°C under artificial lighting, with the lights on between 0600 and 1800 h. Humidity was maintained at 50% ± 5%. Water and dry cat chow pellets (Feline Diet 5003, PMI Feeds, St. Louis, MO, United States) were given *ad libitum*. All experiments were conducted under license from the Government of Hong Kong SAR and with permission from the Animal Experimentation Ethics Committee, The Chinese University of Hong Kong.

Assessment of the Anti-emetic Potential of HM01
-----------------------------------------------

One day before experimentation, the animals were transferred to an observation room with controlled lighting (15 ± 2 Lux) and habituated to clear Perplex observation chambers (21 cm × 14 cm × 13 cm). Food and water were withdrawn immediately before the administration of HM01 (1 to 30 mg/kg, p.o.) or vehicle (distilled water, 2 ml/kg, p.o.). Sixty minutes later, the animals were administered nicotine (5 mg/kg, s.c.), copper sulfate pentahydrate (120 mg/kg, intragastric) or cisplatin (30 mg/kg, i.p.). Food and water were re-introduced 4 h after administration of the test emetogen. The animals' behavior was recorded by an overhead camera (Panasonic WV-CP460/P; Panasonic, Yokahoma, Japan), and data were stored on a digital video recorder (Everfocus EDSR900; Everfocus, Taipei, Taiwan); food and water consumption were recorded during the 4- to 24-h period. In experiments involving provocative motion (1 Hz, 4 cm horizontal displacement for 10 min), the animals were observed for 10 min without assessment of food and water consumption.

Assessment of the Anti-emetic Potential of HM01 in Combination With Palonosetron and/or Netupitant Against Cisplatin-Induced Emesis
-----------------------------------------------------------------------------------------------------------------------------------

Experiments were conducted to determine the potential of palonosetron (0.01--1 mg/k, p.o.) and netupitant (0.1--1 mg/kg, p.o.) to antagonize emesis induced by cisplatin (30 mg/kg, i.p.). The protocol was exactly as stated above for the drug-induced emesis studies. The data were inspected to determine the doses of the antagonists to reduce emesis by approximately 50--60%; similarly, the dose of HM01 that reduced cisplatin-induced emesis was calculated from the drug-induced emesis experiments. Thereafter, palonosetron (0.01 mg/kg, p.o.) and/or netupitant (1 mg/kg, p.o.) were combined with HM01 (3 mg/kg, p.o.) and administered 1 h before cisplatin (30 mg/kg, i.p.); the control animals were treated with vehicle (distilled water, 2 ml/kg, p.o.). Behavior and food and water consumption were measured as stated above.

Drug Formulation
----------------

HM01 (1-\[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl\]-3-methyl-3-\[(4R)-1-Methyl-3,3-dimethyl-4-piperidyl\]urea; **Figure [1](#F1){ref-type="fig"}**) was obtained from Sundia, China. Palonosetron hydrochloride and netupitant were obtained from Helsinn Advanced Synthesis SA, Switzerland. Cisplatin was obtained from Sigma-Aldrich, St. Louis, MO, United States. (-)-Nicotine di-[D]{.smallcaps}-tartrate was obtained from Research Biochemicals, Inc., United States. Copper sulfate pentahydrate was obtained from British Drug Houses, United Kingdom. Cisplatin was dissolved in 0.9% w/v saline solution by gentle warming and adjusted to pH 4 with 0.1 N HCl. All other drugs were dissolved in distilled water. Doses are expressed as the free base.

Measurement of Emesis
---------------------

Emesis was characterized by rhythmical abdominal contractions that were either associated with the forceful oral expulsion of solid or liquid material from the gastrointestinal tract (i.e., vomiting) or not associated with the passage of material (i.e., retching movements). Consecutive episodes of retching and/or vomiting were considered separate when the animal changed its location in the observation cage, or when the interval between episodes exceeded 2 s ([@B56]). At the end of the observation periods, the animals were killed with an intraperitoneal injection of pentobarbitone sodium (80 mg/kg).

Experimental Design and Data Analysis
-------------------------------------

The treatments were randomized and administered following a Latin square design. The investigators were blinded to the treatments. GraphPad Prism 5.0a (GraphPad Software, La Jolla, CA, United States) was used to perform curve fitting (to determine ID~50~ values) and statistical comparisons. Retching, vomiting, body weight and food and water consumption data were analyzed using a one-way analysis of variance followed by Bonferroni's or Dunnett's multiple comparison tests. Latency data were analyzed using a Kruskal--Wallis test followed by Dunn's multiple comparison tests. When an animal failed to retch or vomit, or to eat or drink, a latency value equal to the test period observation time was used to perform the statistical analysis. The results are expressed as the mean ± SEM unless otherwise stated. ID~50~ values were calculated from responses expressed as a percentage of the control data. In all cases, differences between treatment groups were considered significant when the *P*-value was less than 0.05.

Results
=======

Anti-emetic Potential of HM01 Against Emesis Induced by Nicotine, Copper Sulfate, Cisplatin and Motion and Associated Changes in Food and Water Consumption and Body Weight
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Nicotine

Nicotine induced emesis in animals treated with vehicle (0 mg/kg) after a median latency of 3.9 min (quartiles, 2.5 and 8.5 min; **Figure [2](#F2){ref-type="fig"}**). The emetic response comprised 48.6 ± 8.4 retches and 3.0 ± 0.8 vomits in 13.6 ± 2.7 episodes. HM01 did not modify any of the retching and/or vomiting parameters compared with controls (**Figure [2](#F2){ref-type="fig"}**). At the end of the experiments, the animals treated with nicotine and vehicle had lost 3.9% ± 0.5% of their starting body weight (**Figure [3](#F3){ref-type="fig"}**). HM01 at 10 mg/kg caused a significant reduction in nicotine-induced weight loss (approximately 64%; *P* \< 0.05; **Figure [3](#F3){ref-type="fig"}**). The animals treated with nicotine vehicle consumed 3.5 ± 1.9 and 10.3 ± 2.1 g/kg of food and water, respectively, during the 4- to 24-h period (**Figure [3](#F3){ref-type="fig"}**). HM01 caused a significant increase (*P* \< 0.05) in food and water consumption. The effects were maximal at 10 mg/kg, at which a 261.7% increase in food consumption and a 194.0% increase in water consumption were recorded (*P* \< 0.05; **Figure [3](#F3){ref-type="fig"}**). However, HM01 did not affect the latency of the retching or vomiting or the latency of eating or drinking (**Figures [2](#F2){ref-type="fig"}**, **[3](#F3){ref-type="fig"}**).

![Effect of HM01 (3--30 mg/kg, p.o.) administered as a 60 min pretreatment on nicotine (0.5 mg/kg, s.c.)-, copper sulfate (120 mg/kg, i.g.)- and motion (1Hz, 4 cm displacement, 10 min)-induced emesis in *Suncus murinus*. Individual animal latencies to the first episode of retching and/or vomiting, and lines indicating medians with interquartile ranges are shown, as are the number of animals exhibiting retching and/or vomiting out of the number of animals tested. The total number of retches + vomits occurring during the respective observation periods are shown as the mean ± SEM. Significant differences relative to the vehicle-treated animals are indicated as ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 (Kruskal--Wallis test or one-way ANOVA followed by appropriate *post hoc* testing, as appropriate).](fphar-09-00869-g002){#F2}

![Effect of HM01 (3--30 mg/kg, p.o.) administered as a 60 min pretreatment on nicotine (0.5 mg/kg, s.c.)-, copper sulfate (120 mg/kg, i.g.)- and cisplatin (30 mg/kg, i.p.)-induced changes of food and water consumption in *Suncus murinus*. Individual animal latencies to the first episode of eating or drinking, and lines indicating medians with interquartile ranges are shown, as are the number of animals exhibiting eating or drinking out of the number of animals tested. Results represents the mean ± SEM. Significant differences relative to the vehicle-treated animals are indicated as ^∗^*P* \< 0.05 (Kruskal--Wallis test or one-way ANOVA followed by appropriate *post hoc* testing, as appropriate).](fphar-09-00869-g003){#F3}

### Copper Sulfate

Copper sulfate induced emesis in animals treated with vehicle (0 mg/kg) after a median latency of 1.9 min (quartiles, 1.1 and 2.4 min; **Figure [2](#F2){ref-type="fig"}**). The emetic response comprised 52.0 ± 5.9 retches and 6.5 ± 0.8 vomits in 11.5 ± 1.5 episodes. HM01 did not act to modify any of the retching and/or vomiting parameters compared with controls (*P* \> 0.05; **Figure [2](#F2){ref-type="fig"}**). The control animals treated with copper sulfate and vehicle lost 3.7% ± 0.3% of their starting body weight (**Figure [3](#F3){ref-type="fig"}**). HM01 did not modify the copper sulfate--induced weight loss (*P* \> 0.05; **Figure [3](#F3){ref-type="fig"}**). The copper sulfate control animals consumed 0.5 ± 0.5 and 20.2 ± 4.3 g/kg of food and water, respectively; only two of the eight animals ate, and seven of the eight drank. HM01 did not significantly modify food or water consumption (**Figure [3](#F3){ref-type="fig"}**). HM01 also failed to affect the latencies of the retching or vomiting or the latency of eating or drinking (**Figures [2](#F2){ref-type="fig"}**, **[3](#F3){ref-type="fig"}**).

### Motion

Motion induced emesis in animals treated with vehicle (0 mg/kg) after a median latency of 2.7 min (quartiles, 1.2 and 4.2 min; **Figure [2](#F2){ref-type="fig"}**). The emetic response comprised 49.4 ± 10.8 retches + vomits during the 10-min observation period (**Figure [2](#F2){ref-type="fig"}**). HM01 appeared to have a 'U'-shaped dose-response curve; the 10-mg/kg dose significantly reduced the retching and vomiting response by 77.7% (*P* \< 0.05), but it did not affect the latency to the first retch or vomit (*P* \> 0.05; **Figure [2](#F2){ref-type="fig"}**). Food and water consumption parameters were not recorded during this experiment.

### Cisplatin

Cisplatin induced emesis in animals treated with vehicle (0 mg/kg) after a median latency of 0.7 h (quartiles, 0.7 and 0.9 h; **Figure [4](#F4){ref-type="fig"}**). The emetic response comprised 31.6 ± 7.7 retches + vomits during the first 4-h period; 33.4 ± 7.3 retches + vomits occurred during the entire 24-h observation period (**Figure [4](#F4){ref-type="fig"}**). HM01 reduced the retching + vomiting response during the first 4-h period in a dose-dependent manner, with an ID~50~ value of 6.8 ± 3.4 mg/kg; the highest dose of 30 mg/kg completely prevented emesis during this period in all nine animals (*P* \< 0.05). The highest dose of HM01 also reduced retching and vomiting during the entire 24-h period by 80.1%; this reduction was not statistically significant, but six of the nine animals were protected completely (**Figure [4](#F4){ref-type="fig"}**); the latency to the first retching and/or vomiting episode was significantly delayed by approximately 4.6 h (*P* \< 0.05; **Figure [4](#F4){ref-type="fig"}**). The control animals treated with cisplatin and vehicle lost 12.0% ± 1.0% of their starting body weight, but this was not affected by treatment with HM01 (**Figure [3](#F3){ref-type="fig"}**). During the observation period, the controls also ate 29.5 ± 5.8 g of food and consumed 146.1 ± 17.8 ml/kg of water (**Figure [3](#F3){ref-type="fig"}**). The latency to eat after food was introduced into the cage was 3.0 h (quartiles, 0.0 and 9.3 h); HM01 appeared to reduce the latency, but the effect was not statistically significant (**Figure [3](#F3){ref-type="fig"}**). The latency to drink after water was reintroduced into the cage was 5.6 h (quartiles, 0.1 and 6.8 h), and HM01 reduced the latency significantly at 10 mg/kg (*P* \< 0.05; **Figure [3](#F3){ref-type="fig"}**).

![Effect of HM01 (3--30 mg/kg, p.o.) administered as a 60 min pretreatment on cisplatin (30 mg/kg, i.p.)-induced emesis in *Suncus murinus*. Individual animal latencies to the first episode of retching and/or vomiting, and lines indicating medians with interquartile ranges are shown, as are the number of animals exhibiting retching and/or vomiting out of the number of animals tested. The total number of retches + vomits occurring during the respective observation periods are shown as the mean ± SEM. Significant differences relative to the vehicle-treated animals are indicated as ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 (Kruskal--Wallis test or one-way ANOVA followed by appropriate *post hoc* testing, as appropriate).](fphar-09-00869-g004){#F4}

Anti-emetic Potential of HM01 in Combination With Oral Palonosetron and/or Oral Netupitant Against Cisplatin-Induced Emesis and Associated Changes in Food and Water Consumption and Body Weight
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To conduct these experiments, it was necessary to first determine the anti-emetic potential of palonosetron and netupitant alone before designing the combination experiment with HM01.

Effect of Palonosetron Alone Against Cisplatin
----------------------------------------------

Cisplatin induced emesis in animals treated with vehicle (0 mg/kg) after a median latency of 0.7 h (quartiles, 0.6 and 1.1 h; **Figure [5](#F5){ref-type="fig"}**). The emetic response comprised 33.6 ± 12.2 retches + vomits during the first 4-h period; 39.8.4 ± 11.5 retches + vomits occurred during the entire 24-h observation period (**Figure [5](#F5){ref-type="fig"}**). Palonosetron reduced the retching + vomiting response during the first 4-h period in a dose-dependent manner, with an ID~50~ value of 9.8 ± 3.9 μg/kg; the highest dose of 1 mg/kg completely prevented emesis in seven of the eight animals (*P* \< 0.05). The highest dose of palonosetron also reduced retching and vomiting during the entire 24-h period by 84.9% (*P* \< 0.05); three of the eight animals were protected completely (**Figure [5](#F5){ref-type="fig"}**). Palonosetron also produced a dose-related effect that delayed the onset of the first retching and/or vomiting episode: at 0.03 mg/kg, there was a delay of 4.1 h (*P* \< 0.5), and at 1 mg/kg, the delay increased to 6.4 h (*P* \< 0.01). The control animals treated with cisplatin and vehicle lost 10.0% ± 0.9% of their starting body weight, but this was not affected by treatment with palonosetron (**Figure [6](#F6){ref-type="fig"}**). During the observation period, the controls also ate 30.0 ± 8.1 g/kg of food and consumed 91.3 ± 18.5 ml/kg of water (**Figure [6](#F6){ref-type="fig"}**). The latency to eat after food was reintroduced into the cage was 0.9 h (quartiles, 0.1 and 6.0 h). The latency to drink after water was reintroduced into the cage was 0.6 h (quartiles, 0.1 and 2.7 h). Palonosetron did not affect the amount of food or water consumed or the latencies to eat or drink (**Figure [6](#F6){ref-type="fig"}**).

![Effect of palonosetron (0.01--1 mg/kg, p.o.) administered as a 60 min pretreatment on cisplatin (30 mg/kg, i.p.)-induced emesis in *Suncus murinus*. Individual animal latencies to the first episode of retching and/or vomiting, and lines indicating medians with interquartile ranges are shown, as are the number of animals exhibiting retching and/or vomiting out of the number of animals tested. The total number of retches + vomits occurring during the respective observation periods are shown as the mean ± SEM. Significant differences relative to the vehicle-treated animals are indicated as ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 (Kruskal--Wallis test or one-way ANOVA followed by appropriate *post hoc* testing, as appropriate).](fphar-09-00869-g005){#F5}

![Effect of palonosetron (0.01--1 mg/kg, p.o.) and netupitant (0.1--1 mg/kg, p.o.) administered as a 60 min pretreatment on cisplatin (30 mg/kg, i.p.)-induced changes of food and water consumption in *Suncus murinus*. Individual animal latencies to the first episode of eating or drinking, and lines indicating medians with interquartile ranges are shown, as are the number of animals exhibiting eating or drinking out of the number of animals tested. Results represents the mean ± SEM. There were no significant differences relative to vehicle-treated animals (Kruskal--Wallis test or one-way ANOVA).](fphar-09-00869-g006){#F6}

Effect of Netupitant Alone Against Cisplatin
--------------------------------------------

Cisplatin induced emesis in animals treated with vehicle (0 mg/kg) after a median latency of 0.7 h (quartiles, 0.5 and 0.8 h; **Figure [7](#F7){ref-type="fig"}**). The emetic response comprised 52.3 ± 8.7 retches + vomits during the first 4-h period; 53.2 ± 8.5 retches + vomits occurred during the entire 24-h observation period (**Figure [7](#F7){ref-type="fig"}**). Netupitant resulted in a trend to decrease the retching and vomiting response during the first 4-h period and the entire 24-h period; the highest dose of 1 mg/kg reduced the respective responses by 39.5 and 38.8%, but none of the reductions were statistically significant. It was not possible to calculate an ID~50~ value from the data. The control animals treated with cisplatin and vehicle lost 10.7% ± 1.1% of their starting body weight, but this was not affected by treatment with netupitant (**Figure [6](#F6){ref-type="fig"}**). During the observation period, the controls also ate 27.4 ± 6.3 g/kg of food and consumed 71.3 ± 12.6 ml/kg of water (**Figure [6](#F6){ref-type="fig"}**). Netupitant did not affect the amount of food or water consumed, the latencies to the first retch or vomit, or the latencies to eat or drink (**Figure [6](#F6){ref-type="fig"}**).

![Effect of netupitant (0.1--1 mg/kg, p.o.) administered as a 60 min pretreatment on cisplatin (30 mg/kg, i.p.)-induced emesis in *Suncus murinus*. Individual animal latencies to the first episode of retching and/or vomiting, and lines indicating medians with interquartile ranges are shown, as are the number of animals exhibiting retching and/or vomiting out of the number of animals tested. The total number of retches + vomits occurring during the respective observation periods are shown as the mean ± SEM. There were no significant differences relative to vehicle-treated animals (Kruskal--Wallis test or one-way ANOVA).](fphar-09-00869-g007){#F7}

Effect of the Combination of Palonosetron, Netupitant and HM01 Against Cisplatin
--------------------------------------------------------------------------------

We aimed to combine palonosetron, netupitant and HM01 at oral doses that had been shown to reduce emesis by approximately 40%. Therefore, in these studies, palonosetron was used at 0.01 mg/kg, netupitant was used at 1 mg/kg and HM01 was used at 3 mg/kg. In these studies, cisplatin induced emesis in animals treated with vehicle (V+V+V; 0 mg/kg) after a median latency of 0.6 h (quartiles, 0.4 and 0.8 h; **Figure [7](#F7){ref-type="fig"}**). The emetic response comprised 72.6 ± 13.8 retches + vomits during the first 4-h period; 73.8 ± 13.7 retches + vomits occurred during the entire 24-h observation period (**Figure [8](#F8){ref-type="fig"}**). As treatments given alone, palonosetron and HM01 reduced retching and vomiting during the first 4-h period by 71.2% (*P* \< 0.01) and 75.4% (*P* \< 0.001), respectively; their combination produced 92.4% inhibition (*P* \< 0.0001). Netupitant alone produced a reduction of only 43.4% (not statistically significant). When combined with palonosetron, the antagonism of emesis was 74.2% (*P* \< 0.001); when combined with HM01, the reduction was 54.3%, but this result was not statistically significant (**Figure [8](#F8){ref-type="fig"}**). A similar level of inhibition was seen for the entire 24-h period. Thus, as treatments given alone, palonosetron and HM01 reduced retching and vomiting during the entire 24-h period by 62.5% (*P* \< 0.01) and 73.3% (*P* \< 0.001), respectively; their combination produced 83.6% inhibition (*P* \< 0.0001). Netupitant alone produced a reduction of only 42.9% (not statistically significant). When combined with palonosetron, the antagonism of emesis was 66.1% (*P* \< 0.001); when combined with HM01, the reduction was 45.2%, but this result was not statistically significant. The triple combination of palonosetron, netupitant and HM01 produced a significant 82.7% antagonism of emesis (*P* \< 0.0001; **Figure [8](#F8){ref-type="fig"}**). None of the single treatments delayed the onset of the first episode of retching and/or vomiting (**Figure [8](#F8){ref-type="fig"}**). However, palonosetron combined with netupitant delayed the onset by 0.5 h (*P* \< 0.05), palonosetron combined with HM01 delayed the onset by 3.1 h (*P* \< 0.0001) and the triple combination of palonosetron, netupitant and HM01 delayed the onset by 0.8 h (*P* \< 0.001). The control animals treated with cisplatin and vehicle lost 10.0% ± 0.9% of their starting body weight (**Figure [8](#F8){ref-type="fig"}**). During the observation period, the controls ate 30.0 ± 8.1 g/kg of food and consumed 91.3 ± 18.5 ml/kg of water (**Figure [8](#F8){ref-type="fig"}**). None of the treatments affected the amount of weight lost, the amount of food or water consumed, or the latencies to eat or drink (**Figure [8](#F8){ref-type="fig"}**).

![Effect of HM01 (HM) in combination of palonosetron (P) and/or netupitant (N) on cisplatin (30 mg/kg, i.p.)-induced emesis and associated changes in food and water consumption and body weight in *Suncus murinus*. Individual animal latencies to the first episode of eating, drinking, retching and/or vomiting, and lines indicating medians with interquartile ranges are shown, as are the number of animals exhibiting eating, drinking, retching and/or vomiting out of the number of animals tested. Results represents the mean ± SEM. Significant differences relative to the vehicle (V)-treated animals are indicated as ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001 (Kruskal--Wallis test or one-way ANOVA followed by appropriate *post hoc* testing, as appropriate).](fphar-09-00869-g008){#F8}

Discussion
==========

This study is the first to report the unique anti-emetic spectrum of action of the orally bioavailable and brain-penetrating GHS-R1A mimetic, HM01, administered alone and/or in combination with standard anti-emetics such as palonosetron and netupitant. The complete inhibition by HM01 of the emetic response against cisplatin for the first 4 h was comparable with the efficacy of palonosetron (present data) and other 5-HT~3~ receptor antagonists that have been tested in *Suncus murinus* ([@B68]; [@B60]; [@B35]; [@B66]; [@B70]); a decrease in the number of retches and vomits and an increase in the latency to the first episode of emesis were seen. HM01 also antagonized motion-induced emesis, which distinguishes it from 5-HT~3~ receptor antagonists ([@B68]). In fact, the reduction of motion-induced emesis by HM01 in the model appears superior to the action of diphenhydramine and scopolamine ([@B69]), which are the gold-standard anti--motion sickness drugs used in humans ([@B23]). HM01 did not antagonize emesis induced by nicotine or copper sulfate. This differentiates HM01 from the anti-emetic profile of the NK~1~ receptor antagonists, which reduce emesis induced by cisplatin, motion, nicotine and copper sulfate ([@B10]; [@B22]; [@B74]; [@B55]). However, HM01 had positive effects on feeding and drinking after experiments involving nicotine and cisplatin, but not after that involving copper sulfate; the relevance of this finding is discussed below.

HM01 Did Not Affect Emesis Induced by Nicotine or Copper Sulfate
----------------------------------------------------------------

The mechanism by which nicotine induces emesis is not entirely known and may involve an activation of multiple pathways. In dogs, nicotine-induced emesis is prevented by ablation of the area postrema and lesions of the vestibular apparatus; in cats, however, ablation of the area postrema is not effective, and experimentation suggests direct action in the brainstem and the involvement of autonomic ganglia and/or associated end organs in the periphery ([@B36]). The pathways that mediate emesis induced by nicotine in *Suncus murinus* are not known, but the emesis is not blocked by 5-HT~3~ receptor antagonists ([@B68]). Oral administration of copper sulfate induces emesis mainly via the vagus and greater splanchnic nerves, but in contrast to the early emesis induced by cisplatin, the mechanism is not particularly affected by selective 5-HT~3~ receptor antagonists or by ablation of the area postrema ([@B73]; [@B14]; [@B68]). Whilst activation of the vagal afferents by copper sulfate can perturb emetic circuits to other challenges, it presumably occurs at the integrative level of the dorsal vagal complex and not necessarily via the vestibular system ([@B76]). Because the mechanisms and pathways activated by nicotine and copper sulfate are different from those activated by cisplatin and motion, it is not surprising that HM01 was ineffective against these stimuli.

Anti-emetic Spectrum of Activity of HM01
----------------------------------------

Previous studies of the role of GHS-R1A in emesis control used a ferret model. Ghrelin administered by intraperitoneal injection (total dose, 1 mg/kg) produced a non-significant 20% reduction in the number of episodes of retching and/or vomiting ([@B58]). However, when administered into the third ventricle of the brain, ghrelin (10--30 μg) reduced the number of episodes of retching and/or vomiting in a dose-dependent manner, with the maximum reduction reaching approximately 74% ([@B58]). Whilst the anti-emetic action was impressive, it only lasted approximately 30 min, and it was reasoned that this transience was likely due to its relatively short half-life: the half-life in plasma is 30 min in rats and 9--13 min in humans ([@B67]; [@B1]). In comparison, oral administration of HM01 reduced retching and vomiting by 80%, even during the longer 24-h observation period. The half-life of HM01 in *Suncus murinus* is not known, but it about 4.3 h in rats ([@B34]). Analysis of our data shows that HM01 more effectively antagonized emesis induced by cisplatin than that induced by motion. The ID~50~ value of HM01 against the emetic response to cisplatin during the first 4 h was approximately 6.0 mg/kg, and all animals were protected completely at 30 mg/kg. HM01 antagonized motion-induced emesis by approximately 77% at 10 mg/kg, but the effect was lost at 30 mg/kg.

Ghrelin levels have been reported to decrease during testing with an optokinetic stimulus in subjects with visually induced nausea and in patients who are undergoing chemotherapy ([@B40]; [@B20]). In susceptible individuals, motion sickness is hypothesized to involve a mismatch of converging sensory information from the eyes, inner ears and proprioceptive input patterns that differ from learned and expected sensory pattern ([@B8]). The mechanism by which motion induces emesis in *Suncus murinus* is not dependent on the abdominal vagi ([@B50]). Data from studies in *Suncus murinus* and in cats indicate that motion-induced emesis involves pathways in the brainstem nucleus tractus solitarius (NTS; likely to result from descending activation from vestibular input, not gastrointestinal input) and the lateral reticular formation, including the ventrolateral reticular formation, the inferior olive, the vestibular nuclei and the nucleus ambiguus ([@B31], [@B32]; [@B6]; [@B76]). Animals that have undergone labyrinthectomy and people with a defective labyrinth do not normally experience motion sickness or motion-induced emesis, but blind subjects have a normal motion-sickness response ([@B15]). The emesis induced by our motion stimulus was probably driven mainly by the vestibular system, with afferents going to the vestibular nuclei. The early/acute emesis induced by cisplatin, in contrast, involves a peripheral drive of 5-HT (probably from enterochromaffin cells) via 5-HT~3~ receptors on vagal afferents and activation of the NTS and area postrema pathways ([@B54]). However, cisplatin is also known to cause vestibular ototoxicity ([@B59]) and to increase c-fos in the brainstem ([@B13]), where signals from the vestibular nuclei eventually converge after motion ([@B76]). The crossover between the respective mechanisms by which cisplatin and motion induce emesis via hypothalamic, vestibular and medullary pathways interests us the most when we attempt to understand the anti-emetic mechanisms of action of HM01, because GHS-R1A is distributed in these brain areas ([@B11]) and because a history of motion sickness is a risk factor for chemotherapy-induced nausea and emesis in humans ([@B26]).

It is interesting that the effects of HM01 against motion-induced emesis were lost at the higher dose of 30 mg/kg. HM01 is highly selective for GHS-R1A, so off-target effects were not expected ([@B34]). Conversely, HM01 had a clear dose-response relationship to inhibit emesis induced by cisplatin. The difference in dose-response effects may therefore relate to GHS-R1A located in the different pathways modulated by motion and cisplatin. Certainly, it was noted in the original ferret experiments that although ghrelin was anti-emetic, it did appear to induce a few episodes of emesis shortly after intracerebroventricular administration ([@B58]). In our experiments, HM01 was administered orally and would have been gradually absorbed rather than quickly presenting in the brain at a high concentration ([@B34]). We saw no evidence that HM01 itself could induce emesis or could potentiate emesis to any of the emetic challenges that we studied. It is therefore unknown why HM01 was less effective against motion-induced emesis when used at the higher dose (30 mg/kg).

Feeding, Drinking and Weight Loss
---------------------------------

It is known that stimulation of GHS-R1A in the brainstem and hypothalamus are involved in appetite mechanisms, with driving input also involving GHS-R1A on the vagus nerve via the NTS ([@B47]). It is also known that injection of ghrelin into the amygdala inhibits conditioned taste aversion induced by lithium chloride ([@B2]). The hypothalamus, amygdala and brainstem, including the area postrema and the NTS, are involved in the emetic mechanism of action of cisplatin ([@B54]; [@B18]) and in the mechanisms of action of conditioned taste aversion and pica in rats ([@B49]). It is possible, therefore, that HM01 might have reduced 'nausea' and stimulated feeding during the experiments with cisplatin and perhaps other emetic challenges. We expected that animals protected from 'nausea' and emesis would resume feeding and drinking more quickly than the control animals. However, our experiments were primarily designed and powered to record emesis. To reduce the number of animals used, we did not use vehicle control groups for the emetogens. We were interested to find, however, that the baseline food consumption of animals that had received nicotine and copper sulfate differed markedly: animals that received nicotine, copper sulfate and cisplatin ate approximately 3.5, 0.4, and 29.5 g/kg food (24-h recording), respectively; a different pattern was seen in water consumption: 10.3, 20.2, and 146.1 ml/kg (24-h recording), respectively.

In our laboratory, normal untreated adult male *Suncus murinus* eat approximately 100 g/kg food and consume approximately 267 ml/kg of water each day, which agrees with published values ([@B5]). It is likely, therefore, that the three emetic challenges reduced food and water consumption, but by varying degrees. Nevertheless, HM01 only actively increased food and water consumption in the nicotine-treated animals, and this was accompanied by a reduction in weight loss, without affecting the latencies to eat or drink. The relevance of the data is therefore difficult to rationalize to mechanisms of nausea and emesis. However, whilst HM01 did not affect the amounts of food and water consumed in cisplatin-treated animals, it did shorten their latency to drink. These observations must be treated cautiously, but they tend to agree with the view that stimulation of feeding may not necessarily inhibit emetic pathways ([@B29]). Yet we must be cautious in making such assumptions, as other experiments in rats show that the effect of HM01 (dosed orally once per day at 3 and 10 mg/kg) to increase food and water intake requires 1 week to develop ([@B34]) and that the effect manifests more quickly if HM01 is delivered intravenously by osmotic minipumps ([@B34]). It may be that treatment with HM01 must begin several days before the emetic challenge to fully realize any beneficial effect. Although the literature contains no information to conclude that 5-HT~3~ or NK~1~ receptors antagonists can stimulate feeding, both drug classes reduce nausea and vomiting in chemotherapy patients ([@B54]). However, neither palonosetron nor netupitant showed activity to modify the latencies to eat or drink or to affect food and water consumption and body weight loss in animals treated with cisplatin. This finding may indicate that although retching and vomiting was reduced, gastric malaise and/or 'nausea' (if experienced at all), persists via mechanisms that are not regulated by the 5-HT~3~ or NK~1~ receptors.

Usefulness of HM01 in Combination With Palonosetron and/or Netupitant
---------------------------------------------------------------------

Palonosetron is a 'second-generation' 5-HT~3~ receptor antagonist that is approximately ten times more potent than older compounds at blocking 5-HT~3~ receptor and whose plasma half-life is approximately three times longer ([@B75]; [@B25]). A previous study in *Suncus murinus* that did not assess emetic events reported that palonosetron (0.5 mg/kg by intraperitoneal injection) reduced cisplatin-induced (30 mg/kg by intraperitoneal injection) c-fos increase in the NTS, the dorsal motor nucleus of the vagus nerve and the central nucleus of the amygdala at 6 h; these protective effects were not seen in any brain areas when compared at 48 h ([@B18]). In a second study, palonosetron 0.5 mg/kg by subcutaneous injection reduced the number of emetic episodes over the first 24-h period by 87.9% ([@B70]); this finding is highly comparable with the 84.9% inhibition seen after oral administration of 1 mg/kg palonosetron in the present study. Indeed, palonosetron had an ID~50~ of approximately 0.0098 mg/kg, which is similar to its potency in ferrets and dogs in acute experimentation of cisplatin, in which the ID~50~ values were 0.003 and 0.008 mg/kg, respectively ([@B19]). Netupitant (0.3 mg/kg, p.o.) potently reduces cisplatin-induced acute emesis in ferrets by approximately 95%, with an estimated IC~50~ value of 0.1 mg/kg, p.o. ([@B57]). Yet in this present study, netupitant was relatively less potent in reducing cisplatin-induced emesis; a reduction of only around 40% was seen at 3 mg/kg. However, a previous study in *Suncus murinus* found that netupitant could antagonize motion-mediated emesis with an ID~50~ value of 0.08 mg/kg, p.o. ([@B57]). In ferrets, netupitant is known to have a long duration of action of approximately 96 h ([@B57]). If netupitant also has a long half-life in *Suncus murinus*, the difference in potency against emesis induced by cisplatin and by motion is more likely to relate to the relative role of substance P in emetic mechanisms than to its pharmacokinetic profile. In contrast, NK~1~ antagonists are more effective in treating the delayed phase associated with high emetogenic chemotherapy, whereas in this study, our investigation modeled the acute phase more closely. It appears that the pattern of activity of netupitant against motion and cisplatin is shared with other NK~1~ receptor antagonists. Thus, GR203040 (3 mg/kg by subcutaneous injection) produces 77.5 and 53.0% reduction of emesis induced by motion and cisplatin, respectively ([@B21]); another NK~1~-selective antagonist, GR205171 (3 mg/kg by subcutaneous injection), produced 91.2 and 57.2% reductions in emesis induced by motion and cisplatin, respectively ([@B21]); and CP-99944 (10 mg/kg by subcutaneous injection) prevented motion-induced emesis completely ([@B56]) but only reduced cisplatin-induced emesis by 40.7% ([@B37]). This tentatively suggests that the levels of substance P and/or other mediators in emetic circuits may be higher after administration of cisplatin than after motion ([@B3]).

Clearly, the mechanism of action by which HM01 antagonizes emesis differs qualitatively and quantitatively from those of palonosetron and netupitant. We therefore designed experiments to examine the effects of HM01 when combined with suboptimal doses of palonosetron and netupitant. At the doses used alone, none of the treatments could effectively increase the latency to the first emetic episode. However, the combinations of palonosetron plus netupitant, palonosetron plus HM01, and palonosetron plus netupitant and HM01 increased the latency to the first episode. It was not unexpected that palonosetron and netupitant would have useful effects on latency when combined because a similar positive interaction has been observed in ferrets and in humans ([@B45]; [@B57]). Ghrelin has been shown to have beneficial effects against chemotherapy-induced nausea in patients who concurrently receive treatment with the 5-HT~3~ receptor antagonist, ramosetron ([@B28]). In the former study, however, the effects of ghrelin alone were not determined. Our study showed that HM01 had useful effects to increase the latency to the first episode of retching and/or vomiting when used alone (dose ranging study) and when a suboptimal dose was combined with palonosetron, but not with netupitant.

Although we observed a positive interaction between palonosetron and netupitant that increased the latency to the first episode of cisplatin-induced retching and/or vomiting, no interaction was seen to reduce the actual numbers of retches and/or vomits. This differs from clinical observations, in which the combination of palonosetron plus netupitant is better than palonosetron alone against acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy ([@B39]); a positive interaction to reduce retching and vomiting induced by cisplatin has also been seen in the least shrew when assessed over a 16-h period ([@B17]). *Suncus murinus* tachykinin NK~1~ receptors are not rodent- or human-like ([@B3]), but our unpublished studies on *Suncus murinus* isolated ileum revealed that netupitant has a pKb of 8.3 to antagonize \[Sar^9^Met(O~2~)^11^\]--substance P--induced contractions (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**); this is similar to its potency against substance P in guinea pig isolated ileum (pKb = 8.87), but slightly less than expected from binding data on human NK~1~ receptors expressed in CHO cells (pKi = 9) ([@B51]). In contrast, our unpublished data show that palonosetron non-competitively antagonizes 2-methyl-5-HT--induced contractions of *Suncus murinus* isolated ileum, with a pKb of 11 (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**), which is approximately 100 times more potent than in guinea pig ileum to also reduce 2-methyl-5-HT induced contractions (pKb = 8.8) and 10 times more potent compared with binding studies on human hippocampal tissues that express 5-HT~3~ receptors (pKi = 10) ([@B75]). Palonosetron can cause 5-HT~3~ receptor internalization and has unique actions to reduce cross-talk between NK~1~ and 5-HT~3~ receptor signaling pathways, which goes some way to explaining its enhanced efficacy against cisplatin-induced delayed emesis ([@B53]). The acute nature of our cisplatin-induced emesis experiments may explain why we were unable to detect this interaction. Interestingly, it has been reported that GHS-R1A can dimerize with melanocortin-3, dopamine (D~1~ and D~2~) and 5-HT~2C~ receptors ([@B62]). Several of these receptors are involved in emetic mechanisms, but there is no evidence to date that GHS-R1A interacts directly with 5-HT~3~ or NK~1~ receptors.

Conclusion
==========

HM01 was revealed to have useful anti-emetic properties against the chemotherapeutic drug, cisplatin. The anti-emetic effect over the first 4 h appeared comparable with the efficacy of palonosetron and other 5-HT~3~ receptor antagonists previously tested in *Suncus murinus*. Moreover, HM01 also reduced motion-induced emesis, thus revealing for the first time that brain-penetrating GHS-R1A agonists may have clinical utility in the treatment of motion sickness in humans. The link between motion sickness susceptibility and chemotherapy-induced nausea and emesis is well known ([@B64]; [@B9]). We have shown that HM01 was useful alone, in combination with palonosetron and in combination with a palonosetron and netupitant regimen for the control of chemotherapy-induced (acute) emesis; however, it was less useful against emesis induced by pathways modulated by nicotine and intragastric copper sulfate. Given the link between motion sickness susceptibility and post-operative nausea and vomiting ([@B38]) and pregnancy sickness ([@B44]), it is tempting to speculate that GHS-R1A agonists may have greater clinical utility in reducing the side effects of nausea and vomiting in other areas of medicine in which effective and safe drugs are lacking.
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Effect of netupitant on \[Sar^9^Met(O~2~)^11^\]-substance P -induced contractions of *Suncus murinus* isolated ileum **(top)**; double reciprocal plot for \[Sar^9^Met(O~2~)^11^\]-substance P in the presence of 30 nM netupitant **(bottom)**. Data represents the mean ± SEM of 6 determinations.
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Effect of palonosetron on 2-methyl-5-HT-induced contractions of *Suncus murinu*s isolated ileum **(top)**; double reciprocal plot for 2-methyl-5-HT in the presence of 0.03 nM palonosetron **(bottom)**. Data represents the mean ± SEM of 6 determinations.
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